All Quotes

Thank goodness for Congress that is looking out for the American people, not the CFPB.

You've been very generous with your time.

Envisioning a future where progressives change the game and use ballot measures as a political and civic engagement tool for victory.

We don't spend enough on cancer. We need to spend more. I would quadruple the amount of money, if I had my chance, to fight cancer and win.

We are preparing and supporting the designation of a post office for a great American. This is brought to our attention and introduced by Congresswoman Louise Slaughter. It is probably most appropriate that she be the one to tell us more…

We are here today to honor Lieutenant Daniel P. Riordan with a post office naming in St. Louis, Missouri. This has been brought to our attention by Congresswoman Ann Wagner. I appreciate her championing this through the Congress. She is in…

While this is a Senate bill, there is nobody who has been more passionate and excited and dedicated to getting this done than Mr. Garrett of New Jersey. Mr. Speaker, I yield such time as he may consume to the gentleman from New Jersey (Mr…

The United States officially does not take positions on sovereignty issues with respect to territorial and maritime disputes in the East and South China Sea.

Are we currently on schedule to meet this goal?

More than $5 trillion worth of international trade traverses the South China Sea annually.

I am having a hard time seeing why it is that a country like the United States that has used its power, its blood, and its treasure to protect navigation all over the world for 200 years has to, in order to gain some moral high ground…

I would take issue with one aspect of what you said, though, that regardless of what benefits you might see from this, I would not say that signing onto a treaty is without any cost on our part without us giving up anything particularly…

Given the similarity between FDA's draft guidance and the World Health Organization's scheme on biologics qualifiers, it would be important to consult with a WHO in arriving at a global solution.

Has FDA analyzed, No. 1, the extent to which these cost of changing names is passed on to healthcare payers and consumers?

There are a lot of tradeoffs in the naming convention.

Is it possible for FDA to trace adverse events and identify the source without a unique identifier in the name?

I'm very pleased with what you do over there, and I'm particularly pleased with what you're doing in this area.

I do not actually allow that in my committee, because I think it is important that the Administration--or any administration, actually--sits at the same table with those people over whom they make decisions.